BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9055023)

  • 1. Large macroprolactinoma treated with bromocriptine alone.
    Loh KC; Shlossberg AH
    Ann Acad Med Singap; 1996 Nov; 25(6):886-9. PubMed ID: 9055023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.
    Orrego JJ; Chandler WF; Barkan AL
    Pituitary; 2000 Nov; 3(3):189-92. PubMed ID: 11383485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Macroprolactinoma].
    von Werder K
    Dtsch Med Wochenschr; 1996 Jul; 121(30):962. PubMed ID: 8777896
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation].
    Kreft B; Peters A; Kerner W
    Dtsch Med Wochenschr; 1996 Jul; 121(27):865-8. PubMed ID: 8681742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D; Reggiardo D; Sklar C; David R
    Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor.
    Heidari Z; Hosseinpanah F; Shirazian N
    Endocr Pract; 2010; 16(4):669-72. PubMed ID: 20439242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
    Jones SE; James RA; Hall K; Kendall-Taylor P
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical practice. Prolactinomas.
    Klibanski A
    N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
    [No Abstract]   [Full Text] [Related]  

  • 13. Giant macroprolactinoma and pregnancy.
    Saraiva J; Gomes L; Paiva S; Ruas L; Carvalheiro M
    Arq Bras Endocrinol Metabol; 2013 Oct; 57(7):558-61. PubMed ID: 24232822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
    Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
    Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
    Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
    Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
    van 't Verlaat JW; Croughs RJ
    Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.